Navigation Links
United BioSource Expands Regulatory Affairs Capabilities
Date:2/25/2008

Former Pfizer executives to lead regulatory affairs group based in Ann

Arbor, Michigan

BETHESDA, Md., Feb. 25 /PRNewswire/ -- United BioSource Corporation (UBC) today announced the expansion of its Regulatory Affairs group led by distinguished experts Mark Ammann, Pharm.D. and LaVonne Lang, Dr PH. Based in Ann Arbor, Michigan, the group will provide a full range of services to pharmaceutical and biotechnology clients, including creating and implementing development plans to fulfill regulatory requirements for initial approval of new medicines and providing life-cycle management for marketed products.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070910/NEM007LOGO )

The Regulatory Affairs group will be headed by Dr. Mark Ammann, a 17-year veteran of the pharmaceutical industry, who has worked with products from early development to post-marketing product support in such diverse therapeutic areas as CNS, oncology, dermatology, inflammation, endocrinology and cardiovascular disorders. Dr. Ammann most recently held the position of Global Head of Regulatory Affairs at Pfizer Corporation where he was responsible for several therapeutic areas including central nervous system, inflammation and dermatology.

"We are thrilled to welcome Dr. Ammann and Dr. Lang to the UBC team. They give us world-class experience and expertise in navigating through the drug development process with the FDA. This capability complements our specialized regulatory knowledge in areas like health outcomes and post-approval research to provide clients unique regulatory insight in both the pre- and post- approval environment," according to Ethan Leder, UBC CEO and Founder.

"Having led many interactions with the FDA over the past 16 years, I am particularly excited about helping clients navigate through the maze of evolving regulations, offering them counsel about the impact of these changes to their programs," says Dr. Ammann.

Dr. LaVonne Lang will join Ammann in a leadership role, serving as Senior Director, Regulatory Affairs. Dr. Lang has 18 years of experience in pharmaceutical development, with 12 years in positions of increasing responsibility in regulatory strategy at Parke-Davis and Pfizer.

The group will conduct cradle-to-grave global strategic planning, manage submission and liaison activities with health authorities and handle medical writing of regulatory documents. As part of its mandate, they will offer services to both emerging and established life science companies.

United BioSource Corporation (UBC) is a global pharmaceutical services organization that helps emerging and established life science companies develop and commercialize medical products. UBC specializes in offering new and innovative ways to study drugs and devices by offering expertise in science, strategy and execution.

UBC is headquartered in Bethesda, Maryland, with offices in the United States, Canada, Eastern and Western Europe and South America. For more information, visit http://www.unitedbiosource.com or call 866-458-1096.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Mark Ammann, PharmD http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=73619 LaVonne Lang, Dr PH http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=73620


'/>"/>
SOURCE United BioSource Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
2. United States Patent Office Grants CryoCors Request for Patent Interference
3. United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008
4. Energy Conversion Devices and United Solar Ovonic Enter Into New $55 Million Secured Credit Facility Agreements
5. Nycomeds Ciclesonide to be Commercialised in the United States by Sepracor
6. Chindexs United Family Hospitals and Clinics and NBC Enter into Healthcare Services Agreement
7. Neptune Technologies receives GRAS notification in the United States
8. Essilor: New Acquisitions in the United States and Brazil
9. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
10. Medical Services Begins Working With United States Companies for Distribution of Its Products
11. United Therapeutics Reports Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a range ... place between the two entities said Poloz. Speaking ... Ottawa , he pointed to the country,s inflation ... federal government. "In ... "Both institutions have common economic goals, why not sit down ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, ... launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which ... to add Target to its list of well-respected retailers. This list includes such ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
Breaking Biology News(10 mins):